CVRx (CVRX) Accounts Receivable : $8.50 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CVRx Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. CVRx's accounts receivables for the quarter that ended in Mar. 2024 was $8.50 Mil.

Accounts receivable can be measured by Days Sales Outstanding. CVRx's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 71.97.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. CVRx's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $2.41.

CVRx Accounts Receivable Historical Data

The historical data trend for CVRx's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CVRx Accounts Receivable Chart

CVRx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.72

1.28

2.56

5.50

7.55

CVRx Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial													6.43	6.73	6.37	7.55	8.50

CVRx Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

CVRx Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

CVRx's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	8.495	/	10.77	*	91
=	71.97

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), CVRx's accounts receivable are only considered to be worth 75% of book value:

CVRx's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(80.115	+	0.75 * 8.495	+	0.5 * 11.056	-	39.91
-	0	-	0)	/	21.5932
=	2.41

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

CVRx Accounts Receivable Related Terms

Thank you for viewing the detailed overview of CVRx's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

CVRx (CVRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CVRx Inc (NAS:CVRX) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

9201 West Broadway Avenue, Suite 650, Minneapolis, MN, USA, 55445

Website

https://www.cvrx.com

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Executives

Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Paul Verrastro	officer: Chief Marketing Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Kevin Hykes	director	2 GOODYEAR, SUITE B, IRVINE CA 92618
Kirk G. Nielsen	director	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Mudit K. Jain	director	C/O TREO VENTURES, 140 WASHINGTON STREET, SUITE 200, RENO NV 89503
Craig E. Palmer	officer: SVP, U.S. Sales	9201 WEST BROADWAY AVENUE, SUITE 650, MINNEAPOLIS MN 55445
Martha Shadan	director	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
New Enterprise Associates 10 L P	10 percent owner
Nea Partners 10 L P	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Geoffrey B Pardo	director	100 DOMAIN DRIVE, EXETER NH 03833
Jared Oasheim	officer: Chief Financial Officer	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
John Brintnall	officer: Chief Strategy Officer and Sec	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Dean Bruhn-ding	officer: VP of Reg. Affairs and QA	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Liz Galle	officer: VP of Global Clinical Research	9201 W BROADWAY AVE, #650, MINNEAPOLIS MN 55445
Nadim Yared	director, officer: Chief Executive Officer	9201 W BROADWAY AVE #650, MINNEAPOLIS MN 55445